低剂量氯氮平对帕金森病患者左旋多巴诱发的运动障碍的影响。
Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients.
作者信息
Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C
机构信息
Istituto di Clinica delle Malattie Nervose e Mentali, Università La Sapienza, Rome, Italy.
出版信息
Acta Neurol Scand. 1998 May;97(5):295-9. doi: 10.1111/j.1600-0404.1998.tb05955.x.
OBJECTIVES
The aim of this study was to investigate the clinical efficacy of clozapine, an atypical neuroleptic, on L-dopa induced dyskinesias of Parkinson's disease.
MATERIAL AND METHODS
In an open study, a group of 10 PD patients was treated with low dosage clozapine (mean 30 mg/day) for a 4-month period and L-dopa dyskinesias were evaluated in basal conditions and during clozapine treatment after the usual morning dose of clozapine. We utilized the AIMS for evaluation of dyskinesias and UPDRS for the assessment of motor performances.
RESULTS
Clozapine produced a significant (P<0.05) reduction of dyskinesias 1 week after the therapy onset. This effect was more pronounced at the end of the 2nd week and remained stable through the following months. We did not observe significant variations of motor performances.
CONCLUSION
A low dose of clozapine appears to be beneficial for patients with L-dopa induced dyskinesias that do not respond to other drugs and therapeutic measures.
目的
本研究旨在探讨非典型抗精神病药物氯氮平对帕金森病左旋多巴诱发的异动症的临床疗效。
材料与方法
在一项开放性研究中，一组10例帕金森病患者接受低剂量氯氮平（平均30毫克/天）治疗4个月，并在基础状态以及氯氮平治疗期间于每日早晨常规剂量服用氯氮平后评估左旋多巴诱发的异动症。我们使用异动症评估量表（AIMS）评估异动症，并使用统一帕金森病评定量表（UPDRS）评估运动表现。
结果
治疗开始1周后，氯氮平使异动症显著减少（P<0.05）。这种效果在第2周结束时更为明显，并在随后几个月保持稳定。我们未观察到运动表现有显著变化。
结论
低剂量氯氮平似乎对左旋多巴诱发的异动症且对其他药物和治疗措施无反应的患者有益。
Zotero 插件